# Pizarra — PT-pseudo_b9f0b7018502 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9f0b7018502
Task: 1

Encounter: Urology - outpatient on 30 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 8.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: 1.21 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 23.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8609265 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease
  - Problem list / PMHx: Coronary artery disease
  - Current medication: atorvastatin, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.

Vitals: weight 90 kg, height 182 cm, BMI 27.2, BP 97/85 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy.

History: An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact.

Physical examination: DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses.

Patient info: graphic designer; Never married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 5 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.52 +/- 0.20   (95% CI 0.14-0.88)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.5 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=8.7, age=54.0, psad=0.4, dre_ord=0.0, vol=23.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's prior positive biopsy status (which suggests a known diagnosis) against the current high PSA (8.7 ng/mL) and the PI-RADS 5 score. It also could not incorporate the PSA velocity (1.21 ng/mL/yr) or the specific details from the MRI report or lab panel that might contextualize the PI-RADS 5 score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 50/50 split ('discuss' tier). This is problematic because the patient has a prior positive biopsy, which fundamentally changes the question from "Does he have cancer?" to "Is the current elevation due to recurrence, progression, or another cause?" The high csPCa probability (0.86) combined with a PI-RADS 5 score suggests high suspicion, but the prior positive biopsy status might make a repeat biopsy less indicated or change the interpretation of the current findings.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or suspicious lesions not captured by the PI-RADS 5 score, it would increase the need for further investigation.
  <document> PSA history (trend) -> If the PSA velocity is significantly higher than the prior trend, it would increase the urgency for a biopsy.
  <document> previous GP / urology consultation notes -> These notes might clarify the clinical context of the prior positive biopsy and the reason for the current re-evaluation.
  <document> laboratory results (full panel) -> This panel could reveal other markers (e.g., PSA density, other tumor markers) that modify the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Maastricht UMC+ | Department of Radiology | 28 January 2025
  Multiparametric MRI of the Prostate
  Indication: Assessment of elevated prostate-specific antigen (8.7 ng/mL) alongside a previously positive biopsy.
  FINDINGS:
  Glandular volume measures 23.0 mL.
  T2-weighted sequences highlight a discrete hypointense focus located at the base-to-mid transition of the left posterior peripheral zone, spanning roughly 12 mm. Diffusion-weighted imaging demonstrates pronounced restriction with corresponding ADC hypointensity, indicative of marked cellular density. Post-contrast evaluation reveals early, focal, and vigorous enhancement contrasting with adjacent tissue. No extraprostatic extension or seminal vesicle involvement is observed. Pelvic lymph nodes are unremarkable.
  IMPRESSION:
  PI-RADS 5.
  PSAD: 0.4 ng/mL/mL.
  csPCa predicted probability 0.8609265.

  **psa_trend**
  {"case_id": "PT-pseudo_b9f0b7018502", "psa_trend": [{"date": "Jun 2022", "val": 3.1}, {"date": "Feb 2023", "val": 4.0}, {"date": "Oct 2023", "val": 5.2}, {"date": "Jun 2024", "val": 6.7}, {"date": "Jan 2025", "val": 8.7}]}

  **previous_notes**
  {"case_id": "PT-pseudo_b9f0b7018502", "previous_notes": [{"date": "02 Oct 2024", "author": "Dr. L. Smits (GP)", "text": "Clinical review today captured a prostate-specific antigen reading of 8.7 ng/mL, reflecting a distinct increase from the 7.0 ng/mL measurement recorded in June 2024. The patient continues his regimen of atorvastatin and metoprolol for established coronary artery disease, with no new urinary complaints or systemic symptoms reported. His earlier biopsy, which revealed Gleason 3+5 pathology, remains a key reference point in his current workup."}]}

  **lab_results**
  {"case_id": "PT-pseudo_b9f0b7018502", "laboratory_results": [{"name": "PSA", "val": "8.7 ng/mL", "date": "01 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.58 ng/mL", "date": "01 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "18%", "date": "01 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "16.0 g/dL", "date": "01 Jan 2025", "flag": ""}, {"name": "WBC", "val": "5.9 x10^9/L", "date": "01 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "233 x10^9/L", "date": "01 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "82 umol/L", "date": "01 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "01 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "15.8 nmol/L", "date": "01 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "82 U/L", "date": "01 Jan 2025", "flag": ""}, {"name": "LDH", "val": "164 U/L", "date": "01 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the mandate states not to call this tool for this type of workup.

WHAT THE EVIDENCE SUPPORTS
  findings that argue FOR sampling this patient now:
  PI-RADS 5 score
  PSA velocity of 1.21 ng/mL/yr (from initial intake data)
  csPCa predicted probability of 0.8609265

  findings that argue AGAINST sampling this patient now:
  Prior biopsy was Positive (ISUP grade group 4 malignancy)

WHERE THIS LEANS
  The retrieved evidence strongly supports further investigation due to the PI-RADS 5 score and high predicted cancer probability, which aligns with the statistical prior's suggestion to biopsy. However, the prior positive biopsy status introduces significant clinical complexity that the evidence alone cannot resolve.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Given the prior positive biopsy for ISUP grade group 4 malignancy, the question shifts to whether the current findings warrant a change in management. The PI-RADS 5 score and a high csPCa predicted probability of 0.86 strongly argue for further investigation. Although the prior pathology is significant, the high-risk imaging features and rising PSA velocity necessitate a repeat biopsy to assess for progression or recurrence.

Variables that carried weight: bx=decisive, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
